ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on March 11, 2024, under Items 2.02 and 9.01. The filing references financial results for the fourth quarter and full year ended December 31, 2023. The provided filing text does not include the underlying earnings press release.
Financial metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, cash and investments, or operating expenses. These details are contained, or may be contained, in Exhibit 99.1, which was not included in the supplied text.
Material changes versus the prior comparable period
The filing does not describe year-over-year or sequential changes in financial results, operating performance, cash resources, or capital structure.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are provided in the supplied filing text. The filing solely states that the company issued a press release announcing fourth-quarter and full-year 2023 financial results.
Important facts to verify
- Review Exhibit 99.1 for the actual fourth-quarter and full-year 2023 financial results.
- Verify cash, cash equivalents, investments, liquidity runway, operating expenses, and net loss.
- Check for management guidance, clinical-development updates, financing activity, and material risks disclosed in the press release.
- Note that the information furnished under Items 2.02 and 9.01, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.
- Confirm the reporting period: quarter and year ended December 31, 2023.